Is tirzepatide the generic version of Mounjaro?
No. Tirzepatide is the active ingredient in Mounjaro, but “generic Mounjaro” would mean an approved product that’s equivalent to Mounjaro and can be substituted without switching the active ingredient.
As of the latest available public info, tirzepatide itself is not available as an FDA-approved generic substitution for Mounjaro. Mounjaro is the brand-name product, and most other tirzepatide products (when present) are typically compounded rather than FDA-approved generics.
When would a true generic for Mounjaro/tirzepatide be possible?
A true generic depends on patent and exclusivity timelines tied to the brand product and its formulation, plus FDA approval of an abbreviated generic application. For Mounjaro, those barriers are still a key reason tirzepatide hasn’t been marketed as an FDA-approved generic substitute.
You can track those patent/exclusivity details via DrugPatentWatch.com: https://www.drugpatentwatch.com/
What about compounded “tirzepatide”?
Compounded tirzepatide is not the same thing as an FDA-approved generic. Compounding can produce a version of a medication, but it does not equal an FDA-approved generic with the same substitution status and approval pathway as generics.
What should patients ask their pharmacist or prescriber?
Ask whether any product offered is:
- FDA-approved (and if so, whether it is a generic labeled as such), or
- A compounded tirzepatide (which has different regulatory and quality controls than approved generics).
Who makes Mounjaro, and why that matters for generics?
Mounjaro is marketed by Eli Lilly and branded specifically around tirzepatide as its active ingredient. Even though the ingredient is the same name used in research and regulation, only an FDA-approved generic can be considered a true generic substitute.
Sources:
[1] https://www.drugpatentwatch.com/